Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Prelude Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 128

Market Cap: $299.3M

Website

Clinical Trials

A Phase 2 Study of PRT3789 in Combination with Pembrolizumab in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

Phase 2

Recruiting

Conditions: Esophageal Cancer
Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
non-small cell lung cancer (NSCLC)

Interventions: Drug: PRT3789
Drug: pembrolizumab

First Posted Date: 2025-04-16

Last Posted Date: 2025-05-07

Lead Sponsor: Prelude Therapeutics Inc.

Target Recruit Count: 20

Registration Number: 2024-516889-11-00

Locations: 🇩🇪
Goethe University Frankfurt, Frankfurt Am Main, Germany
🇪🇸
Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
🇪🇸
Hospital Quironsalud Barcelona, Barcelona, Spain

and more 2 locations

A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Phase 1

Recruiting

Conditions: Metastatic Solid Tumor
Advanced Solid Tumor
Non-small Cell Lung Carcinoma
SMARCA4 Mutation

Interventions: Drug: PRT7732

First Posted Date: 2024-08-19

Last Posted Date: 2025-06-05

Lead Sponsor: Prelude Therapeutics

Target Recruit Count: 104

Registration Number: NCT06560645

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
Brigitte Harris Cancer Pavilion, Detroit, Michigan, United States

and more 21 locations

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Phase 1

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Mantle Cell Lymphoma (MCL)
Diffuse Large B-cell Lymphoma (DLBCL)
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)
MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome
Richter's Syndrome
T-cell Lymphoma
Chronic Myelomonocytic Leukemia (CMML)

Interventions: Drug: PRT2527
Drug: Zanubrutinib
Drug: Venetoclax

First Posted Date: 2022-12-27

Last Posted Date: 2025-01-20

Lead Sponsor: Prelude Therapeutics

Target Recruit Count: 86

Registration Number: NCT05665530

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 21 locations

PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumor
Metastatic Solid Tumor
Non-small Cell Lung Cancers
SMARCA4 Gene Mutation

Interventions: Drug: PRT3789
Drug: Docetaxel

First Posted Date: 2022-12-06

Last Posted Date: 2025-06-27

Lead Sponsor: Prelude Therapeutics

Target Recruit Count: 135

Registration Number: NCT05639751

Locations: 🇺🇸
University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States
🇺🇸
Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut, United States

and more 29 locations

A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Breast Cancer
Glioblastoma
Head and Neck Squamous Cell Carcinoma
Non-small Cell Lung Cancers
Malignant Mesothelioma
Sarcoma
Endometrial Cancer

Interventions: Drug: PRT3645

First Posted Date: 2022-09-14

Last Posted Date: 2024-07-01

Lead Sponsor: Prelude Therapeutics

Target Recruit Count: 22

Registration Number: NCT05538572

Locations: 🇺🇸
Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut, United States
🇺🇸
AdventHealth Medical Group Oncology Research at Celebration, Celebration, Florida, United States
🇺🇸
Miami Cancer Institute, Miami, Florida, United States

and more 10 locations

A Study of PRT2527 in Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Sarcoma
Hormone Receptor Positive HER2 Negative Breast Cancer
Castrate Resistant Prostate Cancer
Non-small Cell Lung Cancer
Solid Tumors With Known MYC Amplification

Interventions: Drug: PRT2527

First Posted Date: 2021-12-16

Last Posted Date: 2023-12-11

Lead Sponsor: Prelude Therapeutics

Target Recruit Count: 30

Registration Number: NCT05159518

Locations: 🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸
Investigational Drug Services, AdventHealth Celebration, Celebration, Florida, United States
🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States

and more 5 locations

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

Phase 1

Terminated

Conditions: Follicular Lymphoma
Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma
Acute Myeloid Leukemia
Myeloproliferative Neoplasm
Chronic Myelomonocytic Leukemia
Small Lymphocytic Lymphoma
B-cell Non-Hodgkin Lymphoma
Marginal Zone Lymphoma
Myelodysplastic Syndromes

Interventions: Drug: PRT1419
Drug: Azacitidine
Drug: Venetoclax

First Posted Date: 2021-11-04

Last Posted Date: 2024-01-31

Lead Sponsor: Prelude Therapeutics

Target Recruit Count: 21

Registration Number: NCT05107856

Locations: 🇺🇸
Mid Florida Hematology and Oncology Center, Orange City, Florida, United States
🇺🇸
AdventHealth Bone and Marrow Transplant Center, Orlando, Florida, United States
🇺🇸
American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States

and more 6 locations

A Study of PRT1419 in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Sarcoma
Cervical Cancer
Head and Neck Cancer
Lung Cancer
Melanoma
Esophageal Cancer
Breast Cancer

Interventions: Drug: PRT1419

First Posted Date: 2021-04-08

Last Posted Date: 2023-03-15

Lead Sponsor: Prelude Therapeutics

Target Recruit Count: 26

Registration Number: NCT04837677

Locations: 🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

and more 3 locations

A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies

Phase 1

Completed

Conditions: Multiple Myeloma
Acute Myeloid Leukemia
Non Hodgkin Lymphoma
Myelodysplastic Syndromes

Interventions: Drug: PRT1419

First Posted Date: 2020-09-10

Last Posted Date: 2022-11-15

Lead Sponsor: Prelude Therapeutics

Target Recruit Count: 16

Registration Number: NCT04543305

Locations: 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 1 locations

A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas

Phase 1

Completed

Conditions: Advanced Solid Tumor
Recurrent Glioma

Interventions: Drug: PRT811

First Posted Date: 2019-09-13

Last Posted Date: 2023-04-05

Lead Sponsor: Prelude Therapeutics

Target Recruit Count: 86

Registration Number: NCT04089449

Locations: 🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸
Yale- New Haven Hospital- Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
Christiana Care Health Services, Christiana Hospital, Newark, Delaware, United States

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy